Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 272-284

  Hayashi, Takuya ^a,b,c,d   Wakao, Shohei ^e   Kitada, Masaaki ^e   Ose, Takayuki ^a   Watabe, Hiroshi ^a,f   Kuroda, Yasumasa ^e   Mitsunaga, Kanae ^e   Matsuse, Dai ^e   Shigemoto, Taeko ^e   Ito, Akihito ^g   Ikeda, Hironobu ^g   Fukuyama, Hidenao ^c   Onoe, Hirotaka ^a   Tabata, Yasuhiko ^h   Dezawa, Mari ^e  

^a RIKEN   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g Nissei Bilis Co Ltd   (Japan)

^h KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBON 11; DOPAMINE; DOPAMINE TRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARCINOGENICITY; CELL FUNCTION; CELL KINETICS; CELL SURVIVAL; CELL THERAPY; COMPLEMENT FIXATION TEST; CONTROLLED STUDY; CORPUS STRIATUM; DEPOLARIZATION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ENGRAFTMENT; GRAFT RECIPIENT; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LOCOMOTION; LONG TERM SURVIVAL; MACACA; MALE; MESENCHYMAL STEM CELL; MOTOR PERFORMANCE; NERVE CELL DIFFERENTIATION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, DIFFERENTIATION; CORPUS STRIATUM; DOPAMINERGIC NEURONS; GENE EXPRESSION REGULATION; INTEGRIN ALPHA6BETA4; MACACA FASCICULARIS; MALE; MESENCHYMAL STROMAL CELLS; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; TISSUE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 84872585523     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62516     Document Type: Article

References (69)

1. Gage FH. Cell therapy. Nature. 1998; 392(6679 suppl): 18-24.
2. Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res. 2010;184: 265-294.
3. Winkler C, Kirik D, Björklund A. Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci. 2005;28(2): 86-92.
4. Chen X, et al. Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: growth factor production. J Neurosci Res. 2002;69(5): 687-691.
5. Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411): 143-147.
6. Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther. 2010;21(9): 1045-1056.
7. Li Y, et al. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett. 2001;316(2): 67-70.
8. Park HJ, Lee PH, Bang OY, Lee G, Ahn YH. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J Neurochem. 2008;107(1): 141-151.
9. Blandini F, et al. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant. 2010;19(2): 203-217.
10. Venkataramana NK, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res. 2010;155(2): 62-70.
11. Kuroda Y, Kitada M, Wakao S, Dezawa M. Bone marrow mesenchymal cells: how do they contribute to tissue repair and are they really stem cells? Arch Immunol Ther Exp (Warsz). 2011;59(5): 369-378.
12. Wagner W, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One. 2008;3(5):e2213.
13. Moloney TC, et al. Survival and immunogenicity of mesenchymal stem cells from the green fluorescent protein transgenic rat in the adult rat brain. Neurorehabil Neural Repair. 2010;24(7): 645-656.
14. Thompson L, Barraud P, Andersson E, Kirik D, Björklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci. 2005;25(27): 6467-6477.
15. Mendez I, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain. 2005;128(pt 7): 1498-1510.
16. Grealish S, et al. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain. 2010; 133(pt 2): 482-495.
17. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122(pt 8): 1437-1448.
18. Wakao S, et al. Long-term observation of auto-cell transplantation in non-human primate reveals safety and efficiency of bone marrow stromal cell-derived Schwann cells in peripheral nerve regeneration. Exp Neurol. 2010;223(2): 537-547.
19. Hayase M, et al. Committed neural progenitor cells derived from genetically modified bone marrow stromal cells ameliorate deficits in a rat model of stroke. J Cereb Blood Flow Metab. 2009; 29(8): 1409-1420.
20. Dezawa M, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest. 2004; 113(12): 1701-1710.
21. Nagane K, Kitada M, Wakao S, Dezawa M, Tabata Y. Practical induction system for dopamine-producing cells from bone marrow stromal cells using spermine-pullulan-mediated reverse transfection method. Tissue Eng Part A. 2009;15(7): 1655-1665.
22. Sladek JR Jr, Collier TJ, Haber SN, Roth RH, Redmond DE Jr. Survival and growth of fetal catecholamine neurons transplanted into primate brain. Brain Res Bull. 1986;17(6): 809-818.
23. Redmond DE, et al. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet. 1986;1(8490): 1125-1127.
24. Bankiewicz KS, et al. The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. J Neurosurg. 1990;72(2): 231-244.
25. Kordower JH, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000; 290(5492): 767-773.
26. Takagi Y, et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest. 2005; 115(1): 102-109.
27. Eberling JL, et al. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther. 2009; 20(5): 511-518.
28. Ferri ALM, et al. Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. Development. 2007;134(15): 2761-2769.
29. McRitchie DA, Hardman CD, Halliday GM. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J Comp Neurol. 1996;364(1): 121-150.
30. Bankiewicz KS, et al. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 1986;39(1): 7-16.
31. Frey S, et al. An MRI based average macaque monkey stereotaxic atlas and space (MNI monkey space). Neuroimage. 2011;55(4): 1435-1442.
32. Clarke G, et al. A one-hit model of cell death in inherited neuronal degenerations. Nature. 2000; 406(6792): 195-9.
33. Burbach JPH, Smidt MP. Molecular programming of stem cells into mesodiencephalic dopaminergic neurons. Trends Neurosci. 2006;29(11): 601-603.
34. Lindvall O, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990;247(4942): 574-577.
35. Freed CR, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med. 1992;327(22): 1549-1555.
36. Peschanski M, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain. 1994;117(pt 3): 487-499.
37. Spencer DD, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med. 1992;327(22): 1541-1548.
38. Freed CR, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344(10): 710-719.
39. Olanow CW, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54(3): 403-414.
40. Li J-Y, Christophersen NS, Hall V, Soulet D, Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends in Neurosciences. 2008;31(3): 146-153.
41. Vinuela A, et al. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain. 2008; 131(pt 12): 3361-3379.
42. Kittappa R, Chang WW, Awatramani RB, McKay RDG. The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age. PLoS Biol. 2007;5(12):e325.
43. Cooper O, et al. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci. 2010;45(3): 258-266.
44. Cai J, et al. The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson's disease model. Stem Cells. 2009;27(1): 220-229.
45. Hargus G, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA. 2010; 107(36): 15921-15926.
46. Sonntag K-C, et al. Context-dependent neuronal differentiation and germ layer induction of Smad4-/- and Cripto-/- embryonic stem cells. Mol Cell Neurosci. 2005;28(3): 417-429.
47. Kriks S, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011;480(7378): 547-551.
48. O'Keeffe FE, et al. Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain. 2008;131(pt 3): 630-641.
49. Kuan W-L, Lin R, Tyers P, Barker RA. The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol Dis. 2007;25(3): 594-608.
50. De Camilli P, Miller PE, Navone F, Theurkauf WE, Vallee RB. Distribution of microtubule-associated protein 2 in the nervous system of the rat studied by immunofluorescence. Neuroscience. 1984; 11(4): 817-846.
51. Xu H, et al. Transplantation of neuronal cells induced from human mesenchymal stem cells improves neurological functions after stroke without cell fusion. J Neurosci Res. 2010;88(16): 3598-3609.
52. Freeman TB, Brundin P. Important aspects of surgical methodology for transplantation in Parkinson's disease. In: Brundin P, Olanow CW, eds. Restorative Therapies in Parkinson's Disease. New York, New York, USA: Springer; 2006: 131-165.
53. Dubach M, et al. Primate neostriatal neurons containing tyrosine hydroxylase: immunohistochemical evidence. Neurosci Lett. 1987;75(2): 205-210.
54. Guliás B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012;56(2): 173-190.
55. Padma MV, et al. Functional imaging of a large demyelinating lesion. J Clin Neurosci. 2005;12(2): 176-178.
56. Lewis DA, Sesack SR. Dopamine systems in the primate brain. In: Bloom FE, Björklund A, Hökfelt T. The Primate Nervous System. New York, New York, USA: Elsevier; 1997: 263-375.
57. Kordower JH, Liu YT, Winn S, Emerich DF. Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: a behavioral, neuroanatomical, and neurochemical analysis. Cell Transplant. 1995; 4(2): 155-171.
58. Luthman J, Jonsson G. Effects of the parkinsonism- inducing neurotoxin MPTP and its metabolite MPP+ on sympathetic adrenergic nerves in mouse iris and atrium. Med Biol. 1986;64(2-3): 95-102.
59. Kurlan R, Kim MH, Gash DM. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord. 1991;6(2): 111-118.
60. Jordan S, et al. 6-[18F]fluoro-L-m-tyrosine: metab olism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res. 1997;750(1-2): 264-276.
61. Emborg ME, et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol. 1998; 401(2): 253-265.
62. Saiki H, Hayashi T, Takahashi R, Takahashi J. Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease. J Neurosci Methods. 2010;190(2): 198-204.
63. Någren K, Müller L, Halldin C, Swahn CG, Lehikoinen P. Improved synthesis of some commonly used PET radioligands by the use of [11C] methyl triflate. Nucl Med Biol. 1995;22(2): 235-239.
64. Herzog H, et al. NEMA NU2-2001 guided performance evaluation of four Siemens ECAT PET scanners. IEEE Trans Nucl Sci. 2004;51(5): 2662-2669.
65. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6(4): 279-287.
66. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem. 2002;48(8): 1151-1159.
67. Al-Sugair A, Coleman RE. Applications of PET in lung cancer. Semin Nucl Med. 1998;28(4): 303-319.
68. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp. 2002;15(1): 1-25.
69. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44(1): 83-98.